UPDATE: Canaccord Genuity Starts Acorda Therapeutics, Inc. (ACOR) at Hold
Get Alerts ACOR Hot Sheet
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 10
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Hold rating and a price target of $37.00.
Analyst John Newman said, "Phase 3 dalfampridine data in stroke to drive shares: We believe interim data for once-daily fampridine post-stroke should drive value but await visibility given the recent clinical delay. Positive Phase 2 data for dalfampridine-QD suggest Phase 3 data will be positive, despite the change to a two-minute timed walk endpoint. We believe dalfampridine expansion into post-stroke walking deficits could add $357M in peak revenues, with operating leverage based on Acorda’s existing neurology salesforce."
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $35.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Downgrades Pivotree (PVT:CN) to Hold
- JPMorgan Upgrades Millicom International Cellular SA (MIC:SS) (TIGO) to Overweight
- Barclays Downgrades NIBE Industrier AB (NIBEB:SW) (NDRBF) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!